Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	G Medical Innovations Holdings Limited
ARBN 617 204	743

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brendan de Kauwe
Date of last notice	22 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder)	Beneficial Holder Securities registered in the name of -	
Note: Provide details of the circumstances giving rise to the relevant interest.	Attollo Investments Pty Ltd <attollo a="" c="" investment=""></attollo>	
Date of change	18 July 2019	
No. of securities held prior to change	 2,670,455 fully paid ordinary shares 681,818 Class C Performance Rights 2,500,000 unlisted options (\$0.30, 1 May 2020) 	
Class	Fully paid ordinary shares	
Number acquired	500,000	
Number disposed	Nil	
Value/Consideration	Nil consideration. Estimated valuation \$97,500,	
Note: If consideration is non-cash, provide details and	based on closing price of GMV shares on 17 July	
estimated valuation	2019.	
No. of securities held after change	• 3,170,455 fully paid ordinary shares	
	• 681,818 Class C Performance Rights	
	• 2,500,000 unlisted options (\$0.30, 1 May 2020)	
Nature of change	Securities issued to director in accordance with	
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	resolution passed at the Annual General Meeting.	

⁺ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above	No
traded during a ⁺ closed period where prior written clearance	
was required?	
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?	
If prior written clearance was provided, on what date was this	N/A
provided?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.